Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features
© 2024. The Author(s)..
In the ENSEMBLE randomized, placebo-controlled phase 3 trial (NCT04505722), estimated single-dose Ad26.COV2.S vaccine efficacy (VE) was 56% against moderate to severe-critical COVID-19. SARS-CoV-2 Spike sequences were determined from 484 vaccine and 1,067 placebo recipients who acquired COVID-19. In this set of prespecified analyses, we show that in Latin America, VE was significantly lower against Lambda vs. Reference and against Lambda vs. non-Lambda [family-wise error rate (FWER) p < 0.05]. VE differed by residue match vs. mismatch to the vaccine-insert at 16 amino acid positions (4 FWER p < 0.05; 12 q-value ≤ 0.20); significantly decreased with physicochemical-weighted Hamming distance to the vaccine-strain sequence for Spike, receptor-binding domain, N-terminal domain, and S1 (FWER p < 0.001); differed (FWER ≤ 0.05) by distance to the vaccine strain measured by 9 antibody-epitope escape scores and 4 NTD neutralization-impacting features; and decreased (p = 0.011) with neutralization resistance level to vaccinee sera. VE against severe-critical COVID-19 was stable across most sequence features but lower against the most distant viruses.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Nature communications - 15(2024), 1 vom: 11. März, Seite 2175 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Ad26COVS1 |
|---|
| Anmerkungen: |
Date Completed 13.03.2024 Date Revised 25.03.2024 published: Electronic UpdateOf: Res Sq. 2023 May 31;:. - PMID 37398105 Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41467-024-46536-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369573765 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369573765 | ||
| 003 | DE-627 | ||
| 005 | 20240325235151.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240312s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41467-024-46536-w |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1346.xml |
| 035 | |a (DE-627)NLM369573765 | ||
| 035 | |a (NLM)38467646 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Magaret, Craig A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.03.2024 | ||
| 500 | |a Date Revised 25.03.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a UpdateOf: Res Sq. 2023 May 31;:. - PMID 37398105 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a In the ENSEMBLE randomized, placebo-controlled phase 3 trial (NCT04505722), estimated single-dose Ad26.COV2.S vaccine efficacy (VE) was 56% against moderate to severe-critical COVID-19. SARS-CoV-2 Spike sequences were determined from 484 vaccine and 1,067 placebo recipients who acquired COVID-19. In this set of prespecified analyses, we show that in Latin America, VE was significantly lower against Lambda vs. Reference and against Lambda vs. non-Lambda [family-wise error rate (FWER) p < 0.05]. VE differed by residue match vs. mismatch to the vaccine-insert at 16 amino acid positions (4 FWER p < 0.05; 12 q-value ≤ 0.20); significantly decreased with physicochemical-weighted Hamming distance to the vaccine-strain sequence for Spike, receptor-binding domain, N-terminal domain, and S1 (FWER p < 0.001); differed (FWER ≤ 0.05) by distance to the vaccine strain measured by 9 antibody-epitope escape scores and 4 NTD neutralization-impacting features; and decreased (p = 0.011) with neutralization resistance level to vaccinee sera. VE against severe-critical COVID-19 was stable across most sequence features but lower against the most distant viruses | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Ad26COVS1 |2 NLM | |
| 650 | 7 | |a JT2NS6183B |2 NLM | |
| 650 | 7 | |a Amino Acids |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 700 | 1 | |a Li, Li |e verfasserin |4 aut | |
| 700 | 1 | |a deCamp, Allan C |e verfasserin |4 aut | |
| 700 | 1 | |a Rolland, Morgane |e verfasserin |4 aut | |
| 700 | 1 | |a Juraska, Michal |e verfasserin |4 aut | |
| 700 | 1 | |a Williamson, Brian D |e verfasserin |4 aut | |
| 700 | 1 | |a Ludwig, James |e verfasserin |4 aut | |
| 700 | 1 | |a Molitor, Cindy |e verfasserin |4 aut | |
| 700 | 1 | |a Benkeser, David |e verfasserin |4 aut | |
| 700 | 1 | |a Luedtke, Alex |e verfasserin |4 aut | |
| 700 | 1 | |a Simpkins, Brian |e verfasserin |4 aut | |
| 700 | 1 | |a Heng, Fei |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Yanqing |e verfasserin |4 aut | |
| 700 | 1 | |a Carpp, Lindsay N |e verfasserin |4 aut | |
| 700 | 1 | |a Bai, Hongjun |e verfasserin |4 aut | |
| 700 | 1 | |a Dearlove, Bethany L |e verfasserin |4 aut | |
| 700 | 1 | |a Giorgi, Elena E |e verfasserin |4 aut | |
| 700 | 1 | |a Jongeneelen, Mandy |e verfasserin |4 aut | |
| 700 | 1 | |a Brandenburg, Boerries |e verfasserin |4 aut | |
| 700 | 1 | |a McCallum, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Bowen, John E |e verfasserin |4 aut | |
| 700 | 1 | |a Veesler, David |e verfasserin |4 aut | |
| 700 | 1 | |a Sadoff, Jerald |e verfasserin |4 aut | |
| 700 | 1 | |a Gray, Glenda E |e verfasserin |4 aut | |
| 700 | 1 | |a Roels, Sanne |e verfasserin |4 aut | |
| 700 | 1 | |a Vandebosch, An |e verfasserin |4 aut | |
| 700 | 1 | |a Stieh, Daniel J |e verfasserin |4 aut | |
| 700 | 1 | |a Le Gars, Mathieu |e verfasserin |4 aut | |
| 700 | 1 | |a Vingerhoets, Johan |e verfasserin |4 aut | |
| 700 | 1 | |a Grinsztejn, Beatriz |e verfasserin |4 aut | |
| 700 | 1 | |a Goepfert, Paul A |e verfasserin |4 aut | |
| 700 | 1 | |a de Sousa, Leonardo Paiva |e verfasserin |4 aut | |
| 700 | 1 | |a Silva, Mayara Secco Torres |e verfasserin |4 aut | |
| 700 | 1 | |a Casapia, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Losso, Marcelo H |e verfasserin |4 aut | |
| 700 | 1 | |a Little, Susan J |e verfasserin |4 aut | |
| 700 | 1 | |a Gaur, Aditya |e verfasserin |4 aut | |
| 700 | 1 | |a Bekker, Linda-Gail |e verfasserin |4 aut | |
| 700 | 1 | |a Garrett, Nigel |e verfasserin |4 aut | |
| 700 | 1 | |a Truyers, Carla |e verfasserin |4 aut | |
| 700 | 1 | |a Van Dromme, Ilse |e verfasserin |4 aut | |
| 700 | 1 | |a Swann, Edith |e verfasserin |4 aut | |
| 700 | 1 | |a Marovich, Mary A |e verfasserin |4 aut | |
| 700 | 1 | |a Follmann, Dean |e verfasserin |4 aut | |
| 700 | 1 | |a Neuzil, Kathleen M |e verfasserin |4 aut | |
| 700 | 1 | |a Corey, Lawrence |e verfasserin |4 aut | |
| 700 | 1 | |a Greninger, Alexander L |e verfasserin |4 aut | |
| 700 | 1 | |a Roychoudhury, Pavitra |e verfasserin |4 aut | |
| 700 | 1 | |a Hyrien, Ollivier |e verfasserin |4 aut | |
| 700 | 1 | |a Gilbert, Peter B |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature communications |d 2010 |g 15(2024), 1 vom: 11. März, Seite 2175 |w (DE-627)NLM199274525 |x 2041-1723 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2024 |g number:1 |g day:11 |g month:03 |g pages:2175 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41467-024-46536-w |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2024 |e 1 |b 11 |c 03 |h 2175 | ||